1.25Open1.25Pre Close85 Volume23 Open Interest48.50Strike Price10.92KTurnover87.26%IV5.12%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type0.4041Delta0.0906Gamma40.20Leverage Ratio-0.2269Theta0.0019Rho16.24Eff Leverage0.0190Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet